ea0086oc4.5 | Adrenal and Cardiovascular | SFEBES2022
Rees Aled
, Merke Deborah
, Arlt Wiebke
, Pierriere Aude
, Hirschberg Angelica
, Juul Anders
, Newell-Price John
, Perry Colin
, Prete Alessandro
, Reisch Nicole
, Stikkelbroeck Monica
, Touraine Philippe
, Coope Helen
, Lewis Alexander
, Porter John
, Ross Richard
Introduction: First-line treatment for congenital adrenal hyperplasia (CAH) is hydrocortisone1. When adequate control is not achieved, prednisolone (or its prodrug prednisone) are often used. However, there has been no formal comparison of disease control in CAH comparing prednis(ol)one vs hydrocortisone and patients are often on a glucocorticoid dose that exceeds the guideline recommended dose of hydrocortisone (≤25 mg/day)1,2. We report an interim...